NADOLOL by Novartis is clinical pharmacology nadolol tablets, usp is a nonselective beta-adrenergic receptor blocking agent. Approved for hypertension, to lower blood pressure. First approved in 1995.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Nadolol tablets, USP is a nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic…
Worked on NADOLOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma
Oral Nadolol for the Treatment of Adults With Mild Asthma
Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions